
Slovak Pharma Firm Imuna Pharm Returns to Profit Through Asset Sales, But Financial Troubles Persist
Imuna Pharm, eastern Slovakia's best-known pharmaceutical manufacturer, has recorded a profit for the first time in years — but the turnaround rests on shaky foundations. The company returned to the black last year largely by selling off property assets rather than through improved core business performance, while its revenues also increased. Despite the improved headline figures, Imuna Pharm's financial position remains precarious. The company still owes approximately half a million euros in unpaid social and health insurance contributions — known in Slovakia as odvody — which employers are legally required to pay on behalf of their workers. Falling behind on such payments is a significant indicator of ongoing financial strain. Imuna Pharm, based in the eastern Slovak town of Šarišské Michaľany, is one of the region's most prominent industrial employers and has a long history in pharmaceutical production. The company had been experiencing prolonged losses and declining revenues in recent years, making even a property-sale-driven recovery a notable development. However, analysts and observers are likely to view the profit with caution, as gains built on one-time asset disposals do not reflect a sustainable improvement in the underlying business.
















